Rita Nanda to Retreatment
This is a "connection" page, showing publications Rita Nanda has written about Retreatment.
Connection Strength
0.030
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
Score: 0.030